ArticleInternal medicine (Tokyo, Japan)2020

A Low Serum CCL4/MIP-1β Level May Predict a Severe Asthmatic Responsiveness to Mepolizumab.

Maho Suzukawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.